On January 17, 2019, The IMF joined with over 50 patient advocacy groups in an ad campaign to ensure Medicare Part D patients continue to have access to drugs in the Six Protected Classes, which include many drugs used to treat cancer.
This bill ensures fairness in cost-sharing for all anti-cancer regimens. Health insurance cost-sharing schemes should not create barriers to cancer patients' ability to access potentially life-saving medicines.
H.R. 913 aims to improve access to clinical trials for Medicaid enrollees by requiring states to provide coverage of routine patient costs in connection with participation in qualifying clinical trials.